Table 2.
Group | Median sampling time (months) | Lymphocytes (%) | Macrophages (%) | Neutrophils (%) | Eosinophils (%) | |
---|---|---|---|---|---|---|
(a) | AR | |||||
Controls | 4 | A 0 | 3·5 (8) | 87·5 (11) | 3·5 (7·5) | 0 (0) |
6 | A 0 | 5 (7·9) | 91 (13·6) | 7 (5·8) | 0 (0) | |
12 | A 0 | 8·5 (6·1) | 80 (12) | 5 (6·5) | 0 (0) | |
AR | 4 | A 0 | 4 (13·6) | 77 (42·9) | 6·5 (4·1) | 0 (0) |
7 | A 2 | 15 (28·9)* | 78 (29·4)* | 4·5 (5) | 0 (0) | |
12 | A 0 | 15 (17·1) | 82 (12) | 1 (5·1) | 0 (0) |
(b) | OB | |||||
Controls | 3 | – | 2·5 (6·0) | 89·0 (25·9) | 3·5 (7·0) | 0 (0) |
9 | – | 10·0 (16·3) | 80·0 (26·4) | 5·0 (1·6) | 0 (0) | |
18 | – | 7·0 (20·8) | 86·0 (14·5) | 7·0 (3·0) | 0 (0) | |
OB | 3 | – | 8·0 (17·5) | 80·0 (15·5) | 2·0 (5·5) | 0 (0·3) |
9 | – | 51·0 (45·3)* | 47·0 (46·5) | 3·0 (1·3) | 0 (0·3) | |
18 | + | 11·5 (30·0) | 64·0 (18·5)* | 22·0 (18·0)* | 0·5 (1·0) |
Statistically significant difference compared to patients without acute rejection (Wilcoxon's signed-rank: P < 0·05).